Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Theravance’s Vibativ To Get FDA Panel Review For Hospital-Acquired Pneumonia

Sep 19 2012

• By Brenda Sandburg

Related Content

Theravance Gets To Market With Vibativ, But HAP Indication Could Be Pushed To 2010

Sep 14 2009

No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin

Nov 30 2009

Theravance Faces Prospect Of Another Trial For Vibativ In Hospital-Acquired Pneumonia

Jan 29 2010

Related Companies

Innoviva, Inc.

Astellas Pharma, Inc.

Additional Topics

United States Regulation Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window